PEPVERAAUTHENTIC HIGH-QUALITY PEPTIDES
SIGN IN
Cagrilintide
CUT · VI

Cagrilintide

Amylin analogue. The other lever.

From / per milligram
$49$9.8/mg · 5MG
Sizes available
5mg · 10mg
Lab certificate (COA)
Supplier-published sample
Compare 1 suppliers ↓View test certificate →

· Research-grade only · Not for human consumption · 21+ ·

What is it

Amylin analog. Stacks with semaglutide as CagriSema. Phase 3 in progress.

Mechanism · Long-acting amylin receptor agonist. Novo Nordisk CagriSema Phase 3 trials.

Who

Best for. Not for.

Best for

  • Plateau on semaglutide monotherapy. The CagriSema combo adds a second lever.
  • Weight loss plus amylin pathway control (appetite and gastric emptying).
  • Comfortable trying a Phase 3 investigational therapy.

Not for

  • GLP-1 class warnings apply when used in combination.
  • Hypoglycemia risk (T2DM combination therapy).
  • Pregnancy or nursing.
  • Cagrilintide monotherapy is still Phase 2. Standalone data is limited.
What it does

Mechanism, dose, ramp, risk.

Mechanism
Long-acting amylin analogue. Often paired with GLP-1 agonists (Semaglutide / Retatrutide) for synergy.Source · PEPVERA editorial
Target dose
2.4 mg / week.Source · PEPVERA editorial
Ramp
10 weeks paired ramp.Source · PEPVERA editorial
Risks
Nausea synergistic with GLP-1.Source · PEPVERA editorial
Alternatives

Compared to its siblings.

★ Currently viewing

Cagrilintide

Amylin analog. Stacks with semaglutide as CagriSema. Phase 3 in progress.

Pros

  • · Adds amylin pathway lever beyond standalone semaglutide; CagriSema combo exceeds semaglutide monotherapy.
  • · No direct head-to-head loss vs tirzepatide on weight outcomes.

Cons

  • · Semaglutide carries 10+ years of FDA approval and broader insurance coverage.
  • · Tirzepatide is FDA approved with ~21% mean weight loss; cagrilintide remains investigational.

Semaglutide

Standalone GLP-1. The proven monotherapy.

Pros

  • · 10+ Years FDA approved.
  • · Broad insurance coverage.

Cons

  • · Lower weight loss than the CagriSema combo.

See Semaglutide →

Tirzepatide

Dual GLP-1 + GIP. Competitive on a head-to-head basis.

Pros

  • · FDA approved with ~21% mean weight loss.

Cons

  • · No direct head-to-head comparison vs CagriSema.

See Tirzepatide →

How we verify

COA per supplier

Published, in-house, or shipment-time

Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.

→ How we verify suppliers→ Refund policy
Fat lossMetabolicappetite-suppressantExperimentalresearch-only
Suppliers

Compare 2 suppliers

SupplierPriceCOAShips
Ameano PeptidesUS$49$9.80/mg · 5mgSample COA published2 days
Ameano PeptidesUS$88$8.80/mg · 10mgSample COA published2 days
❄ COLD-CHAIN · 5–9 DAYS

Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.

Before you begin

Risk

Nausea synergistic with GLP-1. These pass with discipline. They do not pass with bravado.

Source · PEPVERA editorial

Discipline

10 weeks paired ramp.

Source · PEPVERA editorial

Wellness

Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.

Anti-patterns

  • · Do not pair with stimulants late in the day.
  • · Do not break the cycle without a planned taper.
  • · Do not exceed the dose to chase a deeper sleep response.

Crisis

If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.

Dosing protocol

Week 1–2

0.25 mg / wk

Baseline ramp

Week 3–4

0.5 mg / wk

Hold, observe

Week 5–8

1.0–2.0 mg / wk

Ascend

Week 9–12

2.4 mg / week.

Terminus

Reconstitution

Draw 20 units.

0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.

cut · VI · Ameano Peptides

Cagrilintide · 5mg